Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV ISIN · CA63942R1091 LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2024-05-15 AGM Information
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
Form of proxy - English.pdf
AGM Information Classification · 95% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of NAVCO Pharmaceuticals Inc. It includes instructions for appointing a proxyholder to vote on behalf of shareholders at the AGM, details on voting items such as election of directors, remuneration, and share option plan approval. It also provides procedural notes on proxy submission and voting methods. There are no financial statements or detailed financial data included, nor is this a report or announcement of financial results. The content is clearly related to the AGM meeting process and proxy voting materials, which fits the category of AGM Information (AGM-R). The document length is 5712 characters, sufficient to contain detailed proxy form content but not a full report. Therefore, the correct classification is AGM Information (AGM-R) with high confidence.
2024-05-15 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'Information Circular' and is related to the solicitation of proxies by the management of NAVCO Pharmaceuticals Inc. for use at the annual general meeting (AGM) of its shareholders. It includes detailed proxy voting instructions, information about the meeting date, voting securities, election of directors, and other matters to be acted upon at the AGM. It also references the filing of audited financial statements and management discussion and analysis but does not itself contain financial statements or detailed financial data. The document is a proxy solicitation material, which is typically classified as Proxy Solicitation & Information Statement (PSI). It is not an Annual Report (10-K), nor an Earnings Release, nor a Board/Management change announcement. It is not a report publication announcement since it contains substantive proxy information and voting instructions, not just a notice of report availability. Therefore, the correct classification is PSI with high confidence.
2024-05-15 English
Notice of meeting - English.pdf
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) of shareholders for NAVCO Pharmaceuticals Inc. It outlines the date, location, and agenda of the meeting, including items such as election of directors, appointment of auditors, and approval of a stock option plan. It does not contain financial statements or detailed reports but serves as an announcement and invitation to the AGM. The document length is short (2599 characters), and it explicitly states it is a notice for the AGM, not the AGM materials or presentations themselves. Therefore, it fits the category of AGM Information (AGM-R).
2024-05-15 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a form titled 'Request for Financial Statements' from NAVCO Pharmaceuticals Inc. It allows shareholders to elect to receive annual or interim financial statements and MD&A by mail or email. The document does not contain any financial data, analysis, or report content itself. Instead, it is a request form for shareholders to receive such reports. The document length is short (3595 characters) and it does not present any financial results or management discussion. Therefore, it is not an actual financial report but rather a communication related to distribution of reports. This fits best under Regulatory Filings (RNS) as a general regulatory announcement or communication that does not fit other categories.
2024-05-15 English
Other securityholders documents - English.pdf
Governance Information Classification · 100% confidence The document text is a detailed table of contents or index of corporate bylaws or articles of incorporation, covering topics such as shares, share certificates, share registers, share transfers, meetings of shareholders, voting procedures, directors, election and removal of directors, powers and duties of directors, and disclosure of interests of directors. The content is focused on governance structure, shareholder rights, and internal corporate rules rather than financial performance, audit results, or management commentary. There is no indication of financial data, earnings, audit opinions, or meeting presentations. The document is a governance document outlining the internal rules and procedures of the corporation, which fits the definition of Governance Information (CGR). The length (15,000 characters) and detailed nature confirm it is the actual governance document, not an announcement or summary.
2024-05-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Navco Pharmaceuticals has entered into a marketing contract to increase investor awareness. It does not contain any financial statements, regulatory filings, or detailed financial data. It is a corporate announcement about marketing activities rather than a financial report or regulatory filing. The document length is short (3022 characters) and it is clearly an announcement of a marketing campaign, not a report or filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-04-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.